Vergelijking
CagriSema vs. Maridebart Cafraglutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
geen gegevens
geen gegevens
Molecuulmassa
geen gegevens
geen gegevens
Halfwaardetijd
geen gegevens
geen gegevens
Sequentie
geen gegevens
geen gegevens
Werkingsmechanisme
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
1
1
waarvan bij mensen
1
1
Geregistreerde effecten
2
2
Openstaande tegenstrijdigheden
0
0
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between CagriSema and Maridebart Cafraglutide?
- CagriSema is classified as "Metabool", while Maridebart Cafraglutide is classified as "Metabool". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Maridebart Cafraglutide?
- The highest available evidence level is "Humane RCT" for CagriSema and "Humane RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Maridebart Cafraglutide in Germany and the United States?
- Duitsland: CagriSema — Niet goedgekeurd, Maridebart Cafraglutide — Niet goedgekeurd. Verenigde Staten: CagriSema — Niet goedgekeurd, Maridebart Cafraglutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.